Small Molecule and Biotechnology-Based Therapeutics for Immunology: 2021 IPO Review Pt. VI | https://t.co/wdDBRU7ZFx Dive into the 2021 IPOs for small molecule and biotech-based drugs by immunology-focused companies, including S1P1 modulators, an IL-17 antagonist, and more https https://t.co/LbiN9lg1By
No comments:
Post a Comment